What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Pierfranco Conte focuses on Internal medicine, Oncology, Surgery, Breast cancer and Chemotherapy.
His Internal medicine study frequently draws connections to other fields, such as Gastroenterology.
Pierfranco Conte combines subjects such as Taxane, Cancer, Survival analysis and Trastuzumab with his study of Oncology.
The concepts of his Surgery study are interwoven with issues in Carcinoma and Urology.
His work deals with themes such as Receptor, Metastasis, Adjuvant therapy and Hazard ratio, which intersect with Breast cancer.
His research integrates issues of Survival rate and Capecitabine in his study of Metastatic breast cancer.
His most cited work include:
- Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. (1541 citations)
- Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group (1305 citations)
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation (1004 citations)
What are the main themes of his work throughout his whole career to date?
Pierfranco Conte mainly focuses on Internal medicine, Oncology, Breast cancer, Chemotherapy and Surgery.
His Internal medicine study frequently draws connections to adjacent fields such as Gastroenterology.
His work on Lung cancer is typically connected to In patient as part of general Oncology study, connecting several disciplines of science.
His Breast cancer study incorporates themes from Adjuvant therapy, Cohort and Hazard ratio.
His Chemotherapy research includes elements of Regimen and Ovarian cancer.
His Cancer research incorporates themes from Cancer research and Pathology.
He most often published in these fields:
- Internal medicine (71.95%)
- Oncology (57.28%)
- Breast cancer (34.20%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (71.95%)
- Oncology (57.28%)
- Breast cancer (34.20%)
In recent papers he was focusing on the following fields of study:
Pierfranco Conte mainly investigates Internal medicine, Oncology, Breast cancer, Cancer and Chemotherapy.
Internal medicine is a component of his Metastatic breast cancer, Trastuzumab, Cohort, Hazard ratio and Neoadjuvant therapy studies.
As a member of one scientific family, Pierfranco Conte mostly works in the field of Metastatic breast cancer, focusing on Olaparib and, on occasion, BRCA mutation and Vinorelbine.
When carried out as part of a general Oncology research project, his work on Lung cancer is frequently linked to work in In patient, therefore connecting diverse disciplines of study.
As part of one scientific family, he deals mainly with the area of Breast cancer, narrowing it down to issues related to the Proportional hazards model, and often Retrospective cohort study.
Chemotherapy regimen is the focus of his Chemotherapy research.
Between 2017 and 2021, his most popular works were:
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer (528 citations)
- Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. (198 citations)
- The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial (173 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
His primary scientific interests are in Internal medicine, Oncology, Breast cancer, Chemotherapy and Hazard ratio.
Many of his studies involve connections with topics such as Placebo and Internal medicine.
His Oncology study combines topics in areas such as Stage, Letrozole and Disease.
The study incorporates disciplines such as Gastroenterology, Clinical endpoint, Estrogen and Cancer staging in addition to Breast cancer.
His study on Paclitaxel is often connected to In patient as part of broader study in Chemotherapy.
His research in Hazard ratio focuses on subjects like Proportional hazards model, which are connected to Radiation therapy.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
